Literature DB >> 18646189

Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors.

Christian N Arnold1, Takeshi Nagasaka, Ajay Goel, Iris Scharf, Patricia Grabowski, Andrea Sosnowski, Annette Schmitt-Gräff, C Richard Boland, Rudolf Arnold, Hubert E Blum.   

Abstract

To better understand the molecular pathogenesis of neuroendocrine tumors (NET), we investigated the molecular and clinical characteristics of malignant poorly differentiated colorectal NET and compared these findings with sporadic CRC and well-differentiated benign and malignant fore-/midgut NET. Tumors were analyzed and correlated for microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP). NET were scored for proliferation using Ki-67. A total of 34 malignant poorly differentiated colorectal NET, 38 well-differentiated benign and malignant fore-/midgut-NET and 150 sporadic colorectal cancers (CRC) with known MSI status were investigated. Among the sporadic CRC, CIMP was significantly correlated with MSI-high (MSI-H) (p < 0.001). Of the 34 colorectal NET, 0/1 of the MSI-H, 3/5 (60%) of the MSI-L and 13/19 (68%) of the MSS tumors were CIMP+ (p = 0.17). Of the fore-/midgut-NET, none was MSI-H. 20/34 (59%) colorectal NET vs. 11/38 (29%) fore-/midgut-NET were CIMP+ (p = 0.01). The Ki-67 index was significantly higher in poorly differentiated colorectal NET compared to the less malignant fore-/midgut-NET (p < 0.0001). Besides the location in the colon, Ki-67 predicted poor outcome in NET (p < 0.0001). CIMP status did not affect survival. In NET, p16 methylation predicted a poor outcome (p = 0.0004). We conclude that molecular pathogenesis in sporadic CRC and poorly differentiated colorectal NET is different despite some similarities. Main differences between malignant well-differentiated and poorly differentiated NET are the Ki-67 proliferation rate and differential methylation in tumor-associated genes. Predictors of a poor outcome in patients with NET are poor differentiation, a high Ki-67 index and p16 methylation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18646189      PMCID: PMC2851204          DOI: 10.1002/ijc.23690

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

Review 1.  Connecting proliferation and apoptosis in development and disease.

Authors:  David R Hipfner; Stephen M Cohen
Journal:  Nat Rev Mol Cell Biol       Date:  2004-10       Impact factor: 94.444

Review 2.  Mutator phenotype may be required for multistage carcinogenesis.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

3.  Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system.

Authors:  Christian N Arnold; Andrea Sosnowski; Annette Schmitt-Gräff; Rudolf Arnold; Hubert E Blum
Journal:  Int J Cancer       Date:  2007-05-15       Impact factor: 7.396

4.  Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system.

Authors:  B Terris; M Meddeb; A Marchio; G Danglot; J F Fléjou; J Belghiti; P Ruszniewski; A Bernheim
Journal:  Genes Chromosomes Cancer       Date:  1998-05       Impact factor: 5.006

Review 5.  Epigenetics and human disease.

Authors:  J P Issa; S B Baylin
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

6.  DNA methylation and genetic instability in colorectal cancer cells.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  Genetic instability in colorectal cancers.

Authors:  C Lengauer; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1997-04-10       Impact factor: 49.962

Review 8.  Alterations in DNA methylation: a fundamental aspect of neoplasia.

Authors:  S B Baylin; J G Herman; J R Graff; P M Vertino; J P Issa
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

9.  Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract.

Authors:  Daniela Furlan; Roberta Cerutti; Silvia Uccella; Stefano La Rosa; Elena Rigoli; Anna Genasetti; Carlo Capella
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

Review 10.  Molecular genetics of gastroenteropancreatic endocrine tumors.

Authors:  Aurel Perren; Paul Komminoth; Philipp U Heitz
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

View more
  11 in total

1.  Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential.

Authors:  Arne Warth; Esther Herpel; Sabine Krysa; Hans Hoffmann; Philipp A Schnabel; Peter Schirmacher; Gunhild Mechtersheimer; Hendrik Bläker
Journal:  Exp Mol Med       Date:  2009-05-31       Impact factor: 8.718

Review 2.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 3.  Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

Authors:  P Mapelli; E O Aboagye; J Stebbing; R Sharma
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

Review 4.  Pathologic research update of colorectal neuroendocrine tumors.

Authors:  Shu-Juan Ni; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

5.  Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum.

Authors:  Daniela Furlan; Nora Sahnane; Mara Mazzoni; Roberta Pastorino; Ileana Carnevali; Michele Stefanoli; Andrea Ferretti; Anna Maria Chiaravalli; Stefano La Rosa; Carlo Capella
Journal:  Virchows Arch       Date:  2012-12-09       Impact factor: 4.064

6.  Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making.

Authors:  Uli Fehrenbach; Siyi Xin; Alexander Hartenstein; Timo Alexander Auer; Franziska Dräger; Konrad Froböse; Henning Jann; Martina Mogl; Holger Amthauer; Dominik Geisel; Timm Denecke; Bertram Wiedenmann; Tobias Penzkofer
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 7.  Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Authors:  Emma Elizabeth Ilett; Seppo W Langer; Ingrid Holst Olsen; Birgitte Federspiel; Andreas Kjær; Ulrich Knigge
Journal:  Diagnostics (Basel)       Date:  2015-04-08

8.  Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.

Authors:  Alexander Koenig; Sebastian Krug; Daniela Mueller; Peter J Barth; Ute Koenig; Michael Scharf; Volker Ellenrieder; Patrick Michl; Roland Moll; Kia Homayunfar; Peter Herbert Kann; Philipp Stroebel; Thomas M Gress; Anja Rinke
Journal:  PLoS One       Date:  2017-12-12       Impact factor: 3.240

Review 9.  Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective.

Authors:  Brendan M Finnerty; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey Iii
Journal:  World J Gastrointest Oncol       Date:  2017-09-15

10.  Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.

Authors:  Christoph Fraune; Ronald Simon; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Martina Kluth; Franziska Büscheck; Tania Amin; Fabrice Viol; Wilfrid Fehrle; David Dum; Doris Höflmayer; Eike Burandt; Till Sebastian Clauditz; Daniel Perez; Jakob Izbicki; Waldemar Wilczak; Guido Sauter; Stefan Steurer; Jörg Schrader
Journal:  Endocr Pathol       Date:  2020-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.